The global cancer monoclonal antibodies market was valued at USD 41 billion in 2015 and is expected to surpass USD 68 billion by 2021, says Technavio.
Technavio has announced its latest market research report on the global cancer mAbs market, under its oncology portfolio. This market analysis discusses the major drivers and key emerging trends and offers an analysis of key vendors like F. Hoffmann-La Roche, Amgen, Bristol-Myers Squibb, and Takeda Pharmaceuticals.
According to Sapna Jha, a lead analyst for oncology research at Technavio, “Antibody-drug conjugates are highly effective cytotoxic drugs linked to mAbs, as a result, the market is witnessing an increase in the demand for its use. These drugs have shown to be potent and efficient in treating diseases, including cancers and hematological malignancies.”
The report also states that understanding the nature of diseases at a molecular level increases the development and use of antibodies. The use of ADCs, including radioimmunotherapy and antibody-directed enzyme prodrug therapy, is growing. The growing use of these antibodies in drug development increases revenue generation in the global next-generation biologics market, thereby contributing to the cancer mAbs market growth.
Click here to request a free sample of this report
Emergence of targeted and combination therapies
Targeted and combination therapies are being continuously developed for the treatment of cancers and inflammatory diseases. These therapies, which exploit the surface markers or properties of diseased or infected cells, cause fewer adverse side effects than conventional non-targeted therapies.
Advent of biosimilars expected to improve the treatment rates
The growing demand for quality care has led to the increased use of cancer mAbs. Countries across the globe are under pressure to meet this rising demand without increasing healthcare expenditure. Biosimilars are expected to play a prominent role in this scenario, as, unlike generic drugs, they have similar active pharmaceutical ingredients to their originator biologic compounds. Biosimilars are less expensive than biologics, thereby leading to an increased accessibility.
Ask an analyst to know more about this report
This research report includes an in-depth analysis and market shares and sizes of the sub-segments and geography. An analysis of the key companies, including their market shares, business overview, key financials, etc. is provided in this study. This market study also provides a detailed analysis of key drivers, challenges, and opportunities influencing this market.
A more detailed analysis is available in the Technavio report titled, ‘Global Cancer mAbs Market 2017-2021‘. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Breast Cancer Monoclonal Antibodies Market 2016-2020
- Global Monoclonal Antibodies Market 2016-2020
- Global mAb Biosimilars Market 2016-2020
To read more press releases – click here
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
https://www.technavio.com/
